Explore the Agenda
8:00 am Check In & Morning Coffee
8:50 am Chair’s Opening Remarks
Honing Investment Potential in Exosome Therapeutics to Better Understand Movement in the Field & Optimise Investment in Your Company
9:00 am Understanding the Investment Landscape in Exosome Therapeutics & Evaluating the Risk Return of Clinical Validation & Scalable Platform Opportunity
- Identifying key value drivers from an investor perspective including clinical proof-ofconcept, regulatory clarity, and manufacturability at scale
- Differentiating platforms based on strength of biological rationale, delivery efficiency, and defensibility of intellectual property
- Assessing risk-adjusted return profiles across early-stage assets, focusing on translational milestones and partnering or exit opportunities
9:30 am Session Reserved for Esco Aster
10:00 am Roundtable Discussion: Understanding Investor Perspectives on Exosome Therapeutics to Navigate Risk Reward Clinical Validation & Platform Scalability in a Growing Field
- Exploring how investors assess scientific credibility, clinical maturity, and differentiation within a rapidly evolving exosome landscape
- Debating key risk factors including regulatory uncertainty, manufacturing scalability, and reproducibility of exosome-based products
- Identifying investment catalysts such as early clinical readouts, strategic partnerships, and platform validation across multiple indications
10:30 am Where Can Electron Beam Fit? Evaluating E-Beam Applications Across Exosome Manufacturing and Microbial Control Strategy
- Where e-beam may fit within an exosome manufacturing and microbial control strategy, and where it may not
- Evaluating product, component, and packaging compatibility through feasibility testing before selecting a sterilization approach
- How e-beam can support microbial control while maintaining the quality attributes that matter most
11:00 am Morning Break
Ensuring Batch to Batch Consistency in Exosome Manufacturing to Streamline Manufacturing & Overcome Variability & Scale Up Challenges
11:30 am Ensuring Batch to Batch Consistency in Exosome Manufacturing to Define Critical Quality Attributes & Analytical Control Strategies
- Identifying and controlling critical quality attributes such as particle size distribution, cargo composition, and surface markers to ensure consistent product identity
- Developing robust analytical assays for release testing and in-process monitoring to detect variability early in manufacturing
- Linking manufacturing controls to functional potency to maintain reproducible biological activity across batches
12:00 pm Engineering Scalable Biologics: Gefjon Pharma’s Modular OMV Platform for High‑Yield, Cost‑Effective Production, Powered by NorthX Biologics’ Extensive GMP Manufacturing Expertise
- Outer membrane vesicles (OMVs) are self-adjuvanting bacterial nanoparticles for next-generation vaccines and bioindustrials. This co-presentation introduces Gefjon Pharma’s hyper-vesiculating OMV platform and proprietary extraction method, enabling high-yield, de-risked and cost-effective production of many classes of protein-based pharmaceuticals
- The value of their platform is illustrated by their first asset, a broad-protective E. coli vaccine
- NorthX Biologics then presents the CDMO route to clinical and commercial supply — fermentation process development, scalable purification, and GMP manufacturing — with a focus on preserving yield, purity, and vesicle integrity during scale-up
12:10 pm Lunch
Analyzing The Applications of Exosomes in Inflammatory Diseases & Lethal Indications to Gain A Holistic Understanding of Their Applications
1:10 pm Exosomes Derived from Oligodendrocytes for Therapy of CNS Autoimmune Inflammatory Diseases
- Current therapies for CNS autoimmune diseases are generalized immunosuppressant. There is a clear need for antigen-specific therapies that remove auto-reactive immune cells and leave the rest of immune system intact
- Induction of antigen-specific immunological tolerance can help suppress the autoreactive immune cells without systemic immunosuppression
- Exosomes from the target cells in autoimmune diseases can be used to induce immune tolerance to only target cell antigens, and examples of this novel therapeutic approach will be presented
1:40 pm Session Reserved for NanoFCM
2:10 pm Assessing the Preclinical to Clinical Translation of XOlacta
- Analyzing loading efficiency assessment and PK/PD evaluation
- Understanding the IND process for lethal indications
- Overview of clinical assessments of XOlacta